Please login to the form below

patisiran

This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018.

Alnylam scores EU approval for RNAi drug Givlaari

Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for polyneuropathy in rare disease hereditary ATTR amyloidosis, which was cleared by the FDA in 2018, and Givlaari
FDA clears Alnylam’s second RNAi drug for rare disease

Alnylam was also responsible for the first – Onpattro (patisiran) – which was launched for rare disease hereditary ATTR amyloidosis last year with a $450, 000 per year price tag, dropping to $345,
Alnylam gains key NICE approval for Onpattro

Patisiran has shown in its main clinical study that it can halt or even improve potentially debilitating symptoms of this disease in the majority of patients.

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

How early-stage clinical research is facilitating the new wave of personalised medicines

The first ever siRNA therapy was only approved by the US Food and Drug Administration (FDA) in 2018 – Patisiran for the treatment of the nerve disease (polyneuropathy) – and two further siRNA
20 for 2020 – Five pharma leaders to watch in 2020

So far, its first launch Onpattro (patisiran) has been growing pretty slowly.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Its pivotal APOLLO trial showed nearly all patisiran-treated patients saw the disease halted or slowed, with more than half seeing their neuropathy reversed.
Deal Watch table for January 2014

Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.
Pharma deals during January 2014

The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Account Supervisor – Leading Healthcare Advertising Agency – New...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

PR/ PA Account Executive (UK Healthcare Industry specialist, cam...: Competitive

HR Manager – Recruitment/ Generalist combined role, Marketing ag...: circa £50K

Vaccines writer – career opportunity to move into medcomms from ...: Highly competitive salary

Senior Medical Writer – Creative Healthcare Advertising – New Yo...: Highly Competitive Salary, Bonus &Benefits

Scientific Director, MRNA/ Covid 19, Medical Communications, UK: Six figure salary

Client Services Director, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

Principal Medical Writer, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

Add my company

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Webinar:: Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs): How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials: Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...

Email:
Password: